Amneal Pharmaceuticals, Inc. announced strong first quarter 2024 results, with net revenue of $659 million, an 18% increase compared to the first quarter of 2023. All three segments experienced double-digit top-line growth. The company reached a settlement in principle on a nationwide opioids settlement and affirmed its 2024 full year guidance.
Net revenue for Q1 2024 reached $659 million, an 18% increase year-over-year.
GAAP net loss was $92 million, including a $94 million pre-tax charge for an opioids settlement.
Adjusted EBITDA increased by 31% to $152 million.
Adjusted diluted EPS was $0.14, compared to $0.12 in the first quarter of 2023.
The Company is affirming its previously provided full year 2024 guidance.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance